05/10/2021 (Agence Europe) – On Monday 4 October, the European Medicines Agency began the evaluation of a market authorisation application for the monoclonal antibody Regkirona (CT-P59), which could be used to treat adults with Covid-19 who do not require additional oxygen therapy but are at increased risk of progression to severe Covid-19. The application was submitted by Celltrion Healthcare Hungary Kft and, according to the EMA, could be answered within two months, “depending on the...